Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Current Assets (2020 - 2026)

Design Therapeutics' Current Assets history spans 2 years, with the latest figure at $385.4 million for Q4 2021.

  • On a quarterly basis, Current Assets rose 963.77% to $385.4 million in Q4 2021 year-over-year; TTM through Dec 2021 was $385.4 million, a 963.77% increase, with the full-year FY2021 number at $385.4 million, up 963.77% from a year prior.
  • Current Assets hit $385.4 million in Q4 2021 for Design Therapeutics, down from $395.3 million in the prior quarter.
  • Over the last five years, Current Assets for DSGN hit a ceiling of $411.8 million in Q1 2021 and a floor of $36.2 million in Q4 2020.